CB Therapeutics has developed an innovative and proprietary cellular agriculture platform to efficiently research, discover, develop and produce a wide variety of small- and macro- molecules to positively disrupt traditional manufacturing and drug discovery methods.
We developed in-house structural and bioinformatics programs for novel enzyme design and a rapidly growing IP portfolio platform. Our proprietary and cloud-based automated genome and transcriptome assembly pipeline requires marginal human input and is scalable to vast amounts of next-gen sequencing data.
Advancing Biosynthesis Gene Design
We are utilizing cutting-edge gene design techniques for more robust enzyme expression in proprietary yeast strains. Our novel proprietary enzyme engineering platform has rapidly increased titers and allows for streamlined biosynthetic pathway engineering.
Advancing Process Engineering
Our advanced Bioinformatics platform allows us to conduct complex structural analyses that provide actionable process improvements leading to higher yields with greater efficiency and consistency. Our iterative process allows for progressive product yield improvements and better extraction techniques for multiple yeast-derived high-value products.
Advancing Protein Engineering
Engineering biosynthetic pathways begins with harmonious optimization of multiple functional enzymes rather than just a single one. These functional enzymes and how they come together to enhance product titers are unique to our science. Our bioinformatics and protein engineering platforms have optimized these enzymes to hyper-function in our proprietary yeast strains.
Tryptamines — psilocybin and DMT (N,N-Dimethyltryptamine)
We develop Tryptamines — such as psilocybin, DMT — and their analogs. The molecules produced by CB Therapeutics are pure, environmentally sustainable, chemically consistent, and never contaminated by insecticides or organic materials.
Our biosynthetic production method uses yeast to deliver cannabinoids that are chemically identical to a number of the phytocannabinoids extracted from cannabis and hemp.
The cannabinoids produced this way are pure, environmentally sustainable, chemically consistent, and never contaminated by insecticides or organic materials.
Cellular agriculture – growing meat from cells without harming animals – is no longer a science experiment. In the next three years, companies in this field will introduce dozens of meat, poultry, seafood, and other products into the marketplace, emerging as one of the food world’s most dynamic sectors.